Holen Sie sich die Stockscreener-App
90.78
2.33%
-2.17
Handel nachbörslich:
90.50
-0.28
-0.31%
Schlusskurs vom Vortag:
$92.95
Offen:
$92.81
24-Stunden-Volumen:
4.39M
Relative Volume:
2.28
Marktkapitalisierung:
$18.07B
Einnahmen:
$5.14B
Nettoeinkommen (Verlust:
$1.29B
KGV:
14.18
EPS:
6.4034
Netto-Cashflow:
$1.33B
1W Leistung:
-1.90%
1M Leistung:
-10.40%
6M Leistung:
+4.91%
1J Leistung:
+49.85%
1-Tages-Spanne:
$90.34
$93.34
1-Wochen-Bereich:
$90.34
$94.91
52-Wochen-Spanne:
$53.56
$112.29
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ALNY, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
90.78 | 18.07B | 5.14B | 1.29B | 1.33B | 6.4034 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-02-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-01-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Swiss Life Asset Management Ltd Increases Stake in Incyte Corporation $INCY - MarketBeat
New England Research & Management Inc. Acquires New Stake in Incyte Corporation $INCY - MarketBeat
Incyte Corp. (INCY) reports Q4 2025 revenue growth of 28% to $1.51B driven by Jakafi and Opzelura sales - MSN
INCY wins EC approval for label expansion of oncology drug Zynyz - MSN
Analysts differ in opinion on Jakafi drug maker Incyte (INCY) - MSN
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data a - The National Law Review
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting - The AI Journal
Is Incyte Stock Outperforming the Dow? - Barchart
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
Cutaneous Squamous Cell Carcinoma Pipeline Grows as 45+ Pharma - openPR.com
Cutaneous Squamous Cell Carcinoma Pipeline Grows as 45+ Pharma Companies Advance Novel Skin Cancer Therapies, Finds DelveInsight | Incyte, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Roche, G - Barchart.com
Incyte (NASDAQ:INCY) Insider Sells 18,667 Shares - MarketBeat
Incyte president Pablo Cagnoni sells $1.76 million in stock - Investing.com
Incyte (NASDAQ: INCY) R&D head exercises options, sells 18,667 shares - Stock Titan
Incyte Corp Stock (ISIN: US45337C1027) Faces Pressure Amid Oncology Pipeline Setbacks and Market Vol - AD HOC NEWS
Incyte (INCY) Downgraded by Jefferies; Price Target Lowered | IN - GuruFocus
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Faithward Advisors LLC Takes $4.45 Million Position in Incyte Corporation $INCY - MarketBeat
INCY Stock Price, Quote & Chart | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte’s Latin American MINJUVI Steps Expand Oncology Story Beyond Jakafi - Yahoo Finance
Incyte (INCY) Strengthens Partnership with Knight for MINJUVI in Latin America - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Form 144: INCY (NASDAQ: INCY) reports 18,667-share stock option sale - Stock Titan
INCY's phase III Monjuvi study meets key goals in first-line lymphoma - MSN
Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue (NASDAQ:INCY) - Seeking Alpha
How Diverging Zynyz Outcomes In Cancer Trials At Incyte (INCY) Have Changed Its Investment Story - simplywall.st
Jefferies downgrades Incyte stock rating on patent cliff concerns - Investing.com
Incyte Drug Zynyz Approved in Europe for Anal Canal Cancer Treatment - MyChesCo
How Investors Are Reacting To Incyte (INCY) Winning EU Approval For Zynyz In Advanced Anal Cancer - Yahoo Finance
Incyte Corporation (NASDAQ:INCY) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
INCYIncyte Corp Stock Price and Quote - Finviz
European Commission Approves J&J Prostate Drug, PLX Fabry Dosing, Incyte's Zynyz Second Indication - RTTNews
Mackenzie Financial Corp Has $38.43 Million Stock Holdings in Incyte Corporation $INCY - MarketBeat
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte (INCY) Down 4.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention - MSN
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Incyte Advances New Early Stage Drug INCA033989 Into Human Testing - TipRanks
Incyte at Barclays Conference: Navigating Post-Jakafi Future - Investing.com
Russell Investments Group Ltd. Has $68.44 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Korea Investment CORP Raises Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com
Incyte Corporation $INCY Shares Purchased by Vestcor Inc - MarketBeat
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Finviz
Incyte becomes third company to receive CRL over issues at Novo Indiana factory - Endpoints News
Stifel reiterates Incyte stock rating after FDA setback - Investing.com
Incyte (NASDAQ:INCY) Receives Buy Rating from HC Wainwright - MarketBeat
WINTON GROUP Ltd Acquires 213,557 Shares of Incyte Corporation $INCY - MarketBeat
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):